138 related articles for article (PubMed ID: 18594004)
1. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.
Kim MK; Cho KJ; Kwon GY; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Kim SB
Clin Cancer Res; 2008 Jul; 14(13):4225-31. PubMed ID: 18594004
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
Kim MK; Cho KJ; Kwon GY; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Kim SB
Eur J Cancer; 2008 Jan; 44(1):54-60. PubMed ID: 17976974
[TBL] [Abstract][Full Text] [Related]
3. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
4. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
6. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.
Kang SY; Han JH; Lee KJ; Choi JH; Park JI; Kim HI; Lee HW; Jang JH; Park JS; Kim HC; Kang S; Oh YT; Chun M; Kim JH; Sheen SS; Lim HY
Clin Cancer Res; 2007 Jul; 13(14):4146-53. PubMed ID: 17634542
[TBL] [Abstract][Full Text] [Related]
7. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
[TBL] [Abstract][Full Text] [Related]
8. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.
Gibson MK; Abraham SC; Wu TT; Burtness B; Heitmiller RF; Heath E; Forastiere A
Clin Cancer Res; 2003 Dec; 9(17):6461-8. PubMed ID: 14695149
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
12. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
Scheil-Bertram S; Tylus-Schaaf P; du Bois A; Harter P; Oppitz M; Ewald-Riegler N; Fisseler-Eckhoff A
Gynecol Oncol; 2010 Nov; 119(2):325-31. PubMed ID: 20728204
[TBL] [Abstract][Full Text] [Related]
13. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
Doll CM; Aquino-Parsons C; Pintilie M; Klimowicz AC; Petrillo SK; Milosevic M; Craighead PS; Clarke B; Lees-Miller SP; Fyles AW; Magliocco AM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):721-7. PubMed ID: 22836058
[TBL] [Abstract][Full Text] [Related]
14. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
Hwang IG; Jang JS; Do JH; Kang JH; Lee GW; Oh SY; Kwon HC; Jun HJ; Lim HY; Lee S; Chi KC; Lee SJ
Cancer Chemother Pharmacol; 2011 Oct; 68(4):935-44. PubMed ID: 21298384
[TBL] [Abstract][Full Text] [Related]
15. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
Darcy KM; Tian C; Reed E
Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
[TBL] [Abstract][Full Text] [Related]
16. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
Lee HW; Han JH; Kim JH; Lee MH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS; Lim HY
Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
Hayes M; Lan C; Yan J; Xie Y; Gray T; Amirkhan RH; Dowell JE
Anticancer Res; 2011 Dec; 31(12):4135-9. PubMed ID: 22199271
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma.
Samejima R; Kitajima Y; Yunotani S; Miyazaki K
Anticancer Res; 1999; 19(6C):5515-21. PubMed ID: 10697609
[TBL] [Abstract][Full Text] [Related]
19. Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus.
Chao YK; Chan SC; Chang HK; Liu YH; Wu YC; Hsieh MJ; Tseng CK; Liu HP
Eur J Surg Oncol; 2009 Mar; 35(3):289-94. PubMed ID: 18396384
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas.
Rodrigo RS; Nathalie A; Elodie T; Gonzalo GA; Philippe T; Françoise D; Julien D; Angela C; Bérénice B; Jean-Yves B; Jean-Michel C; Jean B; Sylvie B; Axel le C
Eur J Cancer; 2011 Jun; 47(9):1319-27. PubMed ID: 21450455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
